Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,042	$ 8,417
Short-term investments	11,625	16,915
Accounts receivable	1,406	602
Inventories, net — current	3,812	1,794
Prepaid expenses and other current assets	811	712
Total current assets	31,696	28,440
Restricted cash	2,001
Property and equipment, net	3,539	1,799
Right of use assets	5,826	1,963
Inventories, net — noncurrent	3,485	364
Goodwill	408
Intangible assets, net	370
Other noncurrent assets	23	8
Total assets	47,348	32,574
Current liabilities:
Accounts payable and accrued expenses	4,105	4,685
Amounts due to related parties	80	40
Debt - current	1,141	24
Unearned revenue — current	8	42
Operating lease liability - current	717	611
Other current liabilities	263	306
Total current liabilities	6,314	5,708
Debt - noncurrent	2,105	107
Operating lease liability - noncurrent	5,389	1,497
Common stock warrant liabilities	2,708	14,936
Other noncurrent liabilities	2,280	2,000
Total liabilities	18,796	24,248
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 13,450,861 and 8,646,149 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively.	54	49
Additional paid-in capital	239,496	214,826
Accumulated other comprehensive income		1
Accumulated deficit	(211,825)	(207,171)
Total Arcadia Biosciences stockholders’ equity	27,725	7,705
Non-controlling interest	827	621
Total stockholders' equity	28,552	8,326
Total liabilities and stockholders’ equity	$ 47,348	$ 32,574